Responding to the latest trends in inhalation drug development

By delivering therapeutic concentrations directly to the site of treatment, inhaled medicines can provide a fast onset of action while limiting systemic exposure.

Inhaled medicines have been a critical source of treatment for respiratory diseases for more than 60 years. As a result of the inherent benefits of pulmonary delivery the inhalation drug market is on the rise and more and more companies begin to explore the potential of the dosage form. The rising cases of respiratory diseases across the world, including asthma and chronic obstructive pulmonary disease (COPD), have also acted as a catalyst for this growth.

By delivering therapeutic concentrations directly to the site of treatment, inhaled medicines can provide a fast onset of action while limiting systemic exposure. This also means that smaller doses are possible, minimising the risk of undesirable side effects for patients, while still achieving high efficacy.

In an interview with Drug Development and Delivery, our Global Key Account Director Shabbir Mostafa explores the inhalation drug development market and discusses how inhaled medicines can help with unconventional respiratory diseases.

Read more here.